The study aimed to compare the expression of miR-126-3p and miR-423-5p in patients and normal subjects, and correlate their expression with response to induction therapy. Circulating miR-126-3p and miR-423-5p were measured in the plasma of 43 adult AML patients and 35 age- and sex-matched controls by real time PCR. The foldchange in differential expression for each gene was calculated using the comparative cycle threshold (CT) method (also known as the 2−CT method). For statistical purposes, the fold change was calculated using DDCT (or 2–∆∆Ct) method to find the relative expression of miRNAs. The expression fold change of miR-126-3p was 1.73-fold increase in patients than controls (p= 0.010). The expression fold change of miR-423-5p was a 2.13-fold increase in patients than controls (p=0.003). No significant correlation was found between the expression of miR-126-3p and miR-423-5p in the studied AML patients, (r=0.094, p=0.22). Furthermore, no relationship was found between the expression of the studied miRNAs and response to induction therapy. Conclusions Although a significant increase in the levels of circulating miR126-3p and miR-423-5p expressions was found in AML patients but this was not correlated with induction remission status.
